Cencora, Inc. (NYSE:COR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Cencora, Inc. (NYSE:COR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $275.60.

Several equities research analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an "outperform" rating in a research report on Thursday, November 7th. UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Evercore ISI upped their price objective on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research report on Thursday, November 7th. Bank of America reiterated a "neutral" rating and set a $245.00 price objective (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Finally, Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th.

Cencora Stock Up 0.6 %

COR traded up $1.42 during trading on Friday, reaching $227.69. The company had a trading volume of 1,942,980 shares, compared to its average volume of 1,389,135. The company has a market cap of $44.01 billion, a P/E ratio of 30.32, a PEG ratio of 1.54 and a beta of 0.45. Cencora has a 12 month low of $199.82 and a 12 month high of $253.27. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The business's fifty day moving average price is $239.00 and its 200 day moving average price is $234.09.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.97%. This is a boost from Cencora's previous quarterly dividend of $0.51. Cencora's dividend payout ratio is currently 29.29%.

Insider Activity

In related news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares in the company, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders sold 93,018 shares of company stock valued at $22,478,942. 15.80% of the stock is owned by insiders.

Institutional Trading of Cencora

Institutional investors and hedge funds have recently bought and sold shares of the business. New Millennium Group LLC acquired a new stake in shares of Cencora during the 2nd quarter worth about $26,000. Concord Wealth Partners bought a new position in Cencora in the 3rd quarter valued at about $30,000. SYSTM Wealth Solutions LLC acquired a new stake in Cencora during the second quarter worth approximately $36,000. Ashton Thomas Securities LLC bought a new stake in shares of Cencora during the third quarter worth approximately $41,000. Finally, Family Firm Inc. acquired a new position in shares of Cencora in the second quarter valued at approximately $45,000. Institutional investors own 97.52% of the company's stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.